The drug is manufactured by AMLN, LLY, and ALKS for type II diabetes. Amylin already manufactures a twice-daily formulation of the drug under the brand name Byetta. If approved, exenatide once weekly would be the first and only once-a-week therapy for the treatment of type 2 diabetes.
Prospective clinical trials failed to show any clinical adverse events by the drug in a large population studay of 521 patients. Moreover, the efficacy of the drug far exceeds that of Lagrulitide, its competitor. For details, go on Pubmed.com and pull out the entire results of the trial.